Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2031-08-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged 18 years with locally advanced or metastatic DLL3 positive cancers.